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Early onset schizophrenia (onset before adulthood) is a rare, severe, and chronic form of
schizophrenia.The clinical presentation of schizophrenia at this unusually early age of onset
has been associated with premorbid developmental abnormalities, poor response to neu-
roleptic treatment, greater admission rates, and poor prognosis. This is a brief, condensed
review of current treatment strategies for the early onset population highlighting the need
for novel treatment strategies for these generally treatment-refractory cases. Based on
the current literature, second-generation antipsychotics remain the mainstay of treatment,
although current medications provide suboptimal response at best. Based on the adult lit-
erature, combining antipsychotic treatment with psychotherapeutic intervention may be a
more comprehensive treatment strategy. Indeed, early detection, identiﬁcation of relevant
biomarkers, coupled with advancing knowledge of the neurochemical and neuroanatomic
pathways may help design informed and novel treatment strategies.
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Schizophrenia is a complexpsychiatric disorder afﬂicting 1%of the
population worldwide. The neurodevelopmental model of schiz-
ophrenia posits that the pathophysiology can be traced in the early
stages of development (Weinberger, 1987; Rapoport et al., 1997;
Gogtay et al., 2011). Adolescent onset schizophrenia is less com-
mon and phenotypically more severe. The very early onset form
of this debilitating disorder (childhood onset schizophrenia; onset
of psychosis before age 13) is exceedingly rare, much more severe,
may be homogeneous,with a chronic, treatment-refractory course
(Childs and Scriver, 1986; Sporn et al., 2007). For this review, both
are jointly referred to as early onset schizophrenia (EOS). The early
forms are both phenotypically and neurobiologically continuous
with the adult-onset illness (Jacobsen and Rapoport, 1998; Hol-
lis, 2000), though EOS patients show greater neurodevelopmental
impairments early in life such as delay in language/speech, linguis-
tic ability,motor coordination, and poor psychosocial functioning
(Asarnow et al., 1994; Caplan, 1994; Nicolson and Rapoport, 1999;
Nicolson et al., 2000; McClellan and Werry, 2001; McClellan et al.,
2003; Fleischhaker et al., 2005; Gornick et al., 2005; Vyas et al.,
2007).
The clinical severity and early age at onset in EOS results in
long-term use of antipsychotic medication as a mainstay of treat-
ment, coupled with psychotherapeutic intervention. Increasingly,
efforts are being made toward early detection and management
of prodromal symptoms, which may make it possible to imple-
ment early preventative and treatment strategies before the onset
of the syndromal illness. The use of medication (or treatment
in general) at the prodromal stage, however, has also resulted
in challenging clinical and ethical issues. Therefore, the iden-
tiﬁcation of novel and evidence-based treatment interventions
that effectively improve symptomatology and outcome in EOS is
warranted. We discuss issues relating to prodromal intervention,
followed by a selective review on pharmacological treatment and
psychotherapeutic interventions mostly focusing on EOS. It is
assumed that both treatment modalities are part of a comprehen-
sive treatment plan, involving an initial assessment of the patient,
awareness of the child’s developmental stage, and understanding
of the family system perspective.
EARLY DETECTION AND MANAGEMENT OF PSYCHOSIS
Adolescence is a period of profound changes in the brain struc-
ture with a complex interplay between biological, psychological,
and social factors. Mental health problems commonly emerge in
adolescence and many adolescents have enduring disorders rather
than simply a transient “teenage” emotional turmoil. Individuals
who develop psychosis often experience a prodromal phase (also
known as “at-risk mental state”), which typically involves changes
in perception, behavior, cognition, mood, and physiology (Yung
and McGorry, 1996, McGorry et al., 2001). This phase is ambigu-
ous because of the non-speciﬁcity of symptoms that are commonly
observed during development in adolescence, and the low pre-
dictive power in identifying individuals who make a transition
to psychosis (McGorry and Killackey, 2002). Structured instru-
ments, such as Structured Interview for Prodromal Syndromes
(SIPS; McGlashan et al., 2001), Scale of Prodromal Symptoms
(SOPS; Miller et al., 1999), the Bonn Scale for the Assessment of
Basic Symptoms (BSABS; Gross et al., 1987), the Personal Assess-
ment and Crisis Evaluation (PACE; Phillips et al., 2002), and the
Comprehensive Assessment of At Risk Mental States (CAARMS;
Yung et al., 2004), can help better characterize the prodromal phase
although these lack “predictive” value. In recent years, better char-
acterization of the prodrome phase of the disorder and improved
prediction algorithms have shown to be effective in informing the
timing andmanagement process of early intervention (Cadenhead
et al., 2010). In the PACE study,Yung et al. (2004) conducted a 12-
month follow-up on individuals with ultra high-risk, proposing
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a “four-or-more” algorithm for risk identiﬁcation, including poor
functioning, long duration of symptoms, high levels of depression,
and reduced attention. The algorithm showed a positive predic-
tive value of 80%,with heightened speciﬁcity and sensitivity values
(Yung et al., 2004). In the North American Prodrome Longitudi-
nal Study (NAPLS) cohort, Cannon et al. (2008) followed up 291
treatment-seeking patients with prodromal symptoms at regular
intervals for up to 2.5 years. The study showed conversion rates
to be 35% at follow-up, with baseline characteristics predictive
of psychosis to include a genetic predisposition of schizophre-
nia alongside reduced overall functioning, heightened levels of
abnormal thought content, greater psychosocial impairment, and
a history of substance abuse (Cannon et al., 2008). Similar ﬁnd-
ings have been reported in the European Prediction of Psychosis
(EPOS) study (Ruhrmann et al., 2010). However, there is a paucity
of “biomarkers” for this phase with good predictive value either for
course or treatment response. Although the identiﬁcation of bio-
markers for schizophrenia is in its early stages, some attempts have
been made to discover biomarkers in EOS (Taurines et al., 2010;
Micó et al., 2011). There is limited evidence that management and
symptom speciﬁc treatment of help-seeking prodromal patients
may delay or prevent the onset of psychosis; however the uncer-
tainty of course prediction adds to the risk of stigmatization and
heightened anxiety in individuals and their families. Additionally,
the EOS cases tend to be insidious, non-episodic, and typically
result in rapid deterioration; providing a limited chance to study
and intervene during this window.
The identiﬁcation of biomarkers would improve the ability to
intervene during the prodromal period or earlier. The search for
clinically relevant biomarkers is a challenging task in a heteroge-
neous disorder like schizophrenia but studying EOS provides a
unique opportunity as the phenotype is relatively homogenous,
associated with less risk of secondary inﬂuences from disease
associated alterations of environment (e.g., marijuana, smoking,
hospital admissions, etc.) and typically shows more salient genetic
loading (Vyas et al., 2010, 2011a). Adult studies have attempted
to identify putative biomarkers. For example, a neurocognitive
deﬁcits in schizophrenia is considered a core feature of the ill-
ness (meta-analysis, Heinrichs and Zakzanis, 1998; Heaton et al.,
2001; Keefe and Fenton, 2007) and studies on ultra high-risk
cohorts suggest that impairments in olfactory identiﬁcation and
spatial working memory (measures targeting the dorsolateral pre-
frontal cortex and cortical physiological processes), may have a
strong predictive value for conversion to psychosis (Brewer et al.,
2006). Neurophysiological measures such as electroencephalogra-
phy, event-related potentials, prepulse inhibition, and mismatch
negativity, also show promise as potential biomarkers (Javitt et al.,
2008; Wiedemann, 2011; Vyas et al., 2012) but further work to
elucidate the relationship of such measures with speciﬁc clini-
cal expression (e.g., negative symptoms, cognitive functioning) is
needed. Neuroimaging studies have shown relatively less predic-
tive value despite consistent reports of progressive structural brain
abnormalities associated with schizophrenia (Gogtay et al., 2004;
Rapoport and Gogtay, 2011), and non-psychotic siblings of COS
patients (Gogtay et al., 2003; Greenstein et al., 2011). Some studies
have suggested that high-risk individuals that go on to becomepsy-
chotic show less gray matter volume in the right medial temporal,
lateral temporal, inferior frontal cortex, and in the cingulate cortex
bilaterally, while individuals who do not develop psychosis show
changes restricted to the cerebellum (Pantelis et al., 2003). Such
observations should be strengthened further with multimodal
neuroimaging.
PHARMACOLOGICAL TREATMENT IN EOS
There is a relative dearth of evidence-based studies of antipsy-
chotic (both typical and atypical) efﬁcacy in EOS, partly because
of the rarity of the population and partly because it is difﬁcult
to do treatment trials in children with severe illness (Gogtay
and Rapoport, 2008). Taken together, these studies suggest that
although ﬁrst-generation antipsychotics (FGAs) improve posi-
tive symptomatology, they elicit signiﬁcant extra pyramidal side
effects, tardive dyskinesia, and prolactin elevations (Pool et al.,
1976; Realmuto et al., 1984; Spencer et al., 1992; Findling et al.,
1998).As a result, second-generation antipsychotics (SGA,or atyp-
ical antipsychotics) have become the mainstay of therapy in the
treatment of EOS, because of their potential for lower propen-
sity to induce extrapyramidal symptoms and reduced risk of
tardive dyskinesia (Madaan et al., 2008; Masi and Liboni, 2011).
However the Cochrane review identiﬁed 6 (clinical trials) stud-
ies with a total of 256 children and adolescents, to examine the
effects of antipsychotic medication for EOS (Kennedy et al., 2007).
The SGA used for comparisons were clozapine, risperidone, and
olanzapine. The authors concluded that there was limited data
that supported one antipsychotic medication over another for
the treatment of EOS. There was no superiority of SGAs over
FGAs, given the evidence showing small differences in effect
size for alleviating positive and negative symptoms. Furthermore,
an 8-week, government-funded, randomized double-blind trial
on EOS entitled “Treatment of Early-Onset Schizophrenia Spec-
trum” (TEOSS) showed that SGAs, risperidone and olanzapine,
were not superior to FGA, molindone, in symptom improvement.
Risperidone and olanzapine were associated with high degrees of
weight gain (risperidone additionally showed elevated prolactin
concentration) in comparison with molindone, while individ-
uals prescribed to molindone showed akathisia (Sikich et al.,
2008).
Clozapine remains the gold standard treatment for schizophre-
nia, and has been shown to have a more favorable proﬁle of clinical
response comparedwith haloperidol and olanzapine in treatment-
refractory EOS (Spencer et al., 1992; Mozes et al., 1994; Towbin
et al., 1994; Kumra et al., 1996, 2008; McEvoy et al., 2006). How-
ever, clozapine remains as the last resort choice limited by its
signiﬁcant side effect proﬁle on the hematopoietic system (agran-
ulocytosis), cardiovascular system (myocarditis), central nervous
system (seizures, akinesia, myoclonic jerks), and liver function,
along with other side effects such as severe movement disor-
ders, hypersalivation, hyperglycemia, diabetes, and weight gain,
which are particularly problematic for children and young adults
(Connor et al., 2001; Vyas et al., 2011b).
Clearly, there is an ongoing debate about the efﬁcacy of atypical
medications accounting for the long-term side effects proﬁle, and
therefore there is a pressing need for larger randomized control
trials (RCTs), to delineate the best available antipsychotic agents,
and provide a platform for novel drug discovery.
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PSYCHOTHERAPEUTIC INTERVENTIONS
To date, there are no published RCTs of psychosocial treatments
for children with schizophrenia. However, the adult literature has
supported adjunct psychosocial and individualized psychologi-
cal treatments (Eack et al., 2009; review, Vyas et al., 2012). A
review concluded that psychosocial therapies (cognitive behav-
ioral therapy, CBT), family intervention, social skills training, and
cognitive remediation) are effective adjuncts to pharmacological
interventions in adults with schizophrenia (McGurk et al., 2007;
Patterson and Leewenkamp, 2008). For example, CBT addresses
dysfunctional beliefs, coping strategies,“tuning”of cognitive abili-
ties, and behavior modiﬁcation, by linking and then re-evaluating
thoughts and feelings about the presentation of clinical symp-
toms, which in turn aims to improve the mental states of patients.
Cognitive enhancement therapy has also shown to be effective in
improving neurocognitive functioning in outpatients with EOS
or schizoaffective disorder (Eack et al., 2009). Indeed, family
therapy, psycho-education, and social skills training have also
shown improvement in clinical symptoms of newly diagnosed
patients with schizophrenia (Petersen et al., 2005). A recently pub-
lished multicenter RCT was conducted on young people with
an early initial prodromal state of psychosis, to investigate the
effectiveness of integrated psychological intervention (including
CBT, group skills training, cognitive remediation therapy, and
multifamily psycho-education) and supportive counseling on pre-
vention of psychosis (Bechdolf et al., 2012). The results showed
that the integrated psychological intervention was more effective
in delaying the onset of psychosis over a 24-month follow-up
period (Bechdolf et al., 2012). These studies suggest that psy-
chotherapeutic interventions may thus be an important plat-
form to alleviate psychotic relapse, re-admission, and medication
compliance; systematic validation of such measures however is
warranted.
CONCLUSION AND FUTURE DIRECTIONS
Early onset schizophrenia is a rare, severe, and treatment-
refractory form of the adult-onset illness. Although antipsychotic
treatment, in addition to psychotherapeutic interventions, pro-
vides some symptom relief, there are a very high percentage
of residual psychotic symptoms and cognitive deﬁcits. Existing
medication treatments do not result in adequate response and
the side effects in children remain daunting. Hence, there is a
dire need for early characterization of symptoms and biomarkers,
better understanding of the pathophysiology and progression of
the illness, and exploring novel and “outside the box” treatment
options such as transcranial magnetic stimulation (TMS; Tanaka
and Watanabe, 2009), or transcranial direct current stimulation
(tDCS) trials, which are well tolerated in pediatric populations
(Mattai et al., 2011; Vercammen et al., 2011). Non-invasive neu-
rostimulation techniques such as these have been shown to amelio-
rate cognition and negative symptoms in schizophrenia (Levkovitz
et al., 2011; Minzenberg and Carter, 2012), features commonly
reported in early onset cases (Vyas et al., 2011a). However, new
treatment strategies should be informed by advancing knowl-
edge from neurochemical and neuroanatomic studies, which may
provide more speciﬁc targets in the brain. Recent advances in
neuroimaging methodologies, particularly those that provide a
window into brain functioning and circuitry, may provide a blue-
print for identiﬁcation of novel biomarkers for schizophrenia.
For instance, resting-state and task orientated functional MRI or
magnetoencephalography (MEG) analyses show abnormal brain
synchrony andneural networks in schizophrenia (Reite et al., 1999;
Banaschewski and Brandeis, 2007; Ford et al., 2007; Brookes et al.,
2011; Ikezawa et al., 2011). An ongoing MEG study from our
NIMH COS cohort showed abnormal oscillatory patterns in COS
patients compared to healthy controls (N. S. Vyas, unpublished
data). Treatment strategies could be ideally designed (e.g., region-
ally speciﬁc neuromodulation using tDCS) to “normalize” these
abnormal brain circuitries or evaluate efﬁcacy of new compounds.
Research and implementation of novel treatments coupled with
advances in genome-wide microarray technology may lead to the
identiﬁcation of genes that are relevant not only in the patho-
physiology of schizophrenia, but also in providing an insight into
treatment response, or course prediction.
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